Abstract: The present invention provides stabilization of an extracellular vesicle. Specifically, the present invention provides, for example, a method of stabilizing the extracellular vesicle including mixing an extracellular vesicle-containing sample with a saccharide and a chelating agent.
Abstract: The present invention provides recovering an extracellular vesicle(s) having high purity from an extracellular vesicle-containing sample. Specifically, the present invention provides a method of recovering an extracellular vesicle(s), comprising: (1) treating an extracellular vesicle-containing sample with a chelating agent; and (2) separating the extracellular vesicle(s) from the extracellular vesicle-containing sample treated with the chelating agent.
Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.
Type:
Application
Filed:
March 15, 2017
Publication date:
June 6, 2019
Applicants:
NATIONAL CANCER CENTER, Miraca Research Institute G.K.
Abstract: The present invention provides a method for adequately analyzing a target DNA after genomic DNA cleavage reaction with a restriction enzyme. More specifically, the present invention provides a method for measuring a target DNA, including (1) cleaving a genomic DNA with a restriction enzyme in a solution to obtain a mixed solution containing (a) completely cleaved DNA fragments consisting of the target DNA, (b) incompletely cleaved DNA fragments comprising the target DNA, and (c) DNA fragments not comprising the target DNA; (2) removing the DNA fragments of (b) from said mixed solution to obtain a solution containing the DNA fragment of (a) and the DNA fragments of (c); and (3) analyzing the target DNA in the solution obtained in (2).
Abstract: The present invention provides a novel marker for diagnosing fibromyalgia syndrome (FMS). More specifically, the present invention provides a method for diagnosing FMS, comprising measurement of (1) the relative frequency of MAITs to the total T cells in a sample; or (2) the expression level of one or more surface antigens selected from the group consisting of CD4, CD8, CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8?, CD44 and CXCR4 for MAITs in a sample, wherein the sample is a biological sample collected from a human; and a diagnosis kit for FMS, comprising a means for measuring (1) the relative frequency of MAITs to the total T cells in a sample; or (2) the expression level of one or more surface antigens selected from the group consisting of CD4, CD8, CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8?, CD44 and CXCR4 for MAITs in a sample, wherein the sample is a biological sample collected from a human.
Type:
Grant
Filed:
March 24, 2016
Date of Patent:
December 18, 2018
Assignees:
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, MIRACA RESEARCH INSTITUTE G.K.